TICKERNERD
Menu
ATRAATRAHealthcare · Biotechnology

ATRA Stock Forecast: Atara Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$8.53
−1.50% on the day

The 3 Wall Street analysts covering Atara Biotherapeutics, Inc. hold a median 12-month price target of $13 — +52.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$83.3M
Ticker Nerd rank
58/ 100
Median analyst target
$13
Analysts covering
3
Revenue$630K−96.4% y/y
Operating income−$4.7M
Net income−$4.8M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.5%
1M
+6.0%
YTD
−52.8%
1Y
−39.3%
From 52W high
−52.8%
From 52W low
+104.1%
$4
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atara Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
77
Size
75
Quality
74
Revisions
73
Issuance
68
Accruals
48
Volatility
28
Momentum
19
Growth
10

Value (77): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26ATRAHigh $18Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $10Median $13High $18

The green dot is the last close — the median target sits +52.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026Freedom BrokerUpgradeHold$4.00 → $10
8 May 2026Canaccord GenuityUpgradeBuy—
21 Jan 2026Freedom BrokerDowngradeSell—
13 Jan 2026Canaccord GenuityDowngradeHold—
19 Dec 2025Canaccord GenuityMaintainsBuy—
11 Mar 2025Canaccord GenuityMaintainsBuy—
28 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
22 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
17 Jan 2025Canaccord GenuityMaintainsBuy—
20 Dec 2024Rodman & RenshawInitiatesBuy—
13 Nov 2024Canaccord GenuityMaintainsBuy—
21 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
16 Aug 2024MizuhoUpgradeOutperform—
13 Aug 2024Canaccord GenuityMaintainsBuy—
17 July 2024Goldman SachsMaintainsSell—
22 May 2024HC Wainwright & Co.ReiteratesNeutral—
1 Apr 2024StifelMaintainsHold—
10 Nov 2023Goldman SachsMaintainsSell—
9 Nov 2023Evercore ISI GroupDowngradeIn-Line—
9 Nov 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ATRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ATRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Atara Biotherapeutics, Inc. returned −39.3% against +13.6% for the S&P 500, dividends included.

ATRA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26ATRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Atara Biotherapeutics, Inc. (ATRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
13.5×

Cheaper than 11% of US stocks

Price / book
−3.3×

Cheaper than 96% of US stocks

EV / EBITDA
−7.5×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−96.4%

Higher than 2% of US stocks

Earnings growth (YoY)
−96.4%

Higher than 2% of US stocks

Gross margin
69.7%

Higher than 82% of US stocks

Operating margin
−627.5%

Higher than 7% of US stocks

Net margin
−269.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−84.9%

Higher than 15% of US stocks

Return on assets
−24.1%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Atara Biotherapeutics, Inc. (ATRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Atara Biotherapeutics, Inc. has a market value of $83.3M and an enterprise value of $83.3M.

  • Revenue in the twelve months to 30 June 2026: $6.2M. The latest quarter shrank 96.4% year on year.

  • Net income over the same four quarters: −$16.7M, a −269.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$21.9M.

  • Shares outstanding: 9.4M.

  • Trailing P/E: 3.8×; forward P/E: 5.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Atara Biotherapeutics, Inc. employs 10 people — $619K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

ATRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATRAAtara Biotherapeutics, Inc.$83.3M58
NTHINeOnc Technologies Holdings, Inc.$87.3M20
CNXUConexeu Sciences, Inc.$88.8M1
RLYBRallybio Corp.$84.4M60
EQEquillium, Inc.$89.8M37
RANIRani Therapeutics Holdings, Inc.$83.9M73
TNYATenaya Therapeutics, Inc.$92.0M35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atara Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATRA news & analysis

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Business Wire · 14 Oct 2026positive

Atara Biotherapeutics reported that the FDA accepted the resubmitted Biologics License Application for tabelecleucel. The application was resubmitted by its partner, Pierre Fabre Pharmaceuticals.

Why it matters — The FDA’s acceptance is a regulatory development concerning tabelecleucel, a therapy being developed by Atara and its partner.

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Business Wire · 30 Sept 2026positive

Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, has resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration. The company provided the update regarding the regulatory submission for its T-cell immunotherapy candidate.

Why it matters — The resubmission is a key regulatory step for tabelecleucel, a lead candidate in Atara's pipeline, advancing its path toward potential FDA approval.

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Business Wire · 12 Aug 2026neutral

Atara Biotherapeutics reported its financial results for the second quarter of 2026 and provided business updates. The company noted it and its partner, Pierre Fabre Pharmaceuticals, held a productive Type A meeting with regulators during the quarter.

Why it matters — ATRA watchers would care because the quarterly update and the productive Type A meeting with partner Pierre Fabre signal progress in the company's regulatory and development efforts.

FAQ

Frequently asked questions about ATRA stock

What is the ATRA stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Atara Biotherapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATRA stock a buy right now?

Of the 3 analysts covering Atara Biotherapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atara Biotherapeutics, Inc. 58 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATRA?

As at 28 Oct 2026, Atara Biotherapeutics, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (77 of 100).

Will ATRA stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +52.4% from the last close, and Ticker Nerd's factor model ranks Atara Biotherapeutics, Inc. 58 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATRA stock forecast for 2030?

No analyst covering Atara Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $18 over the next 12 months.

How has ATRA stock performed over the past year?

Atara Biotherapeutics, Inc. returned -39.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atara Biotherapeutics, Inc. do?

Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy.

What is the latest news on ATRA?

The most recent item we track (Business Wire, 14 Oct 2026): "Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration". Atara Biotherapeutics reported that the FDA accepted the resubmitted Biologics License Application for tabelecleucel. The application was resubmitted by its partner, Pierre Fabre Pharmaceuticals.

Company

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Its current portfolio centers on Epstein-Barr virus (EBV)-targeted T-cell programs and next-generation CAR T candidates, reflecting a platform built to harness donor-derived immune cells for precision treatment approaches. The company’s product development activities include therapies aimed at EBV-driven diseases and B-cell malignancies, positioning it within the broader cell therapy and immuno-oncology markets. Headquartered in Thousand Oaks, California, Atara Biotherapeutics serves the evolving demand for advanced immunotherapies that can be manufactured and deployed without traditional patient-specific cell engineering.

CEO Dr. Anhco Nguyen Ph.D. · 10 employees · United States · https://www.atarabio.com